Get the Stockscreener App
9.70
7.27%
-0.76
After Hours:
9.94
0.24
+2.47%
Edesa Biotech Inc stock is traded at $9.70, with a volume of 236.82K.
It is down -7.27% in the last 24 hours and up +33.61% over the past month.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
See More
Previous Close:
$10.46
Open:
$10.43
24h Volume:
236.82K
Relative Volume:
0.05
Market Cap:
$86.25M
Revenue:
-
Net Income/Loss:
$-7.82M
P/E Ratio:
-8.4605
EPS:
-1.1465
Net Cash Flow:
$-8.00M
1W Performance:
-18.83%
1M Performance:
+33.61%
6M Performance:
+467.25%
1Y Performance:
+394.90%
1-Day Range:
$9.65
$11.38
1-Week Range:
$9.65
$12.72
52-Week Range:
$0.72
$20.32
Edesa Biotech Inc Stock (EDSA) Company Profile
Name
Edesa Biotech Inc
Sector
Industry
Phone
(905) 475-1234
Address
100 SPY COURT, MARKHAM, ON
Compare EDSA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
9.70 | 93.01M | 0 | -7.82M | -8.00M | -1.1465 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Edesa Biotech Inc Stock (EDSA) Latest News
Edesa Biotech, Inc. (EDSA) Presents at Dermatology Drug Development Summit 2026Slideshow - Seeking Alpha
Edesa Biotech, Inc.Common Shares (NQ: EDSA - FinancialContent
EDSA: Preparing for Mid-2026 Start to Phase 2 Vitiligo Trial - Zacks Small Cap Research
Edesa Biotech Inc. (EDSA) Q1 2026 Earnings: Wider Than Expected Loss as Clinical Pipeline ProgressesExpert Momentum Signals - Newser
EDSA Should I Buy - Intellectia AI
EDSA Stock Price, Quote & Chart | EDESA BIOTECH INC (NASDAQ:EDSA) - ChartMill
Key facts: Edesa Biotech Q2 Loss $4.2M; to Present AKI Data - TradingView
Edesa Biotech, Inc. (EDSA) Presents at Respiratory Innovation Summit 2026Slideshow (NASDAQ:EDSA) 2026-05-19 - Seeking Alpha
What's going on in today's session - ChartMill
Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference - GlobeNewswire
Stonepine entities report 30,000-share stake in Edesa Biotech (EDSA) - Stock Titan
EDESA (EDSA) Schedule 13G/A amendment: Nantahala and principals report 0 shares - Stock Titan
Point72, Steven Cohen report 2 Edesa Biotech shares (NASDAQ: EDSA) - Stock Titan
Rubric Capital and Rosen Hold 7.74% of EDSA (NASDAQ: EDSA) - Stock Titan
Edesa Biotech to issue 90% of CEO’s salary as restricted share units - Investing.com UK
Edesa Biotech Boosts CEO Equity-Based Compensation Structure - TipRanks
Edesa Biotech 8-K Filing: Board Approves CEO Compensatory Arrangements – Key Details from May 2026 SEC Report - Minichart
Edesa Biotech | 8-K: Current report - Moomoo
Edesa Biotech (NASDAQ: EDSA) CEO opts to receive 90% of salary in RSUs - Stock Titan
Sirenia (EDSA) discloses 600,000-share, 7.2% stake in Edesa Biotech - Stock Titan
Edesa Biotech Advances on Two Fronts, Tackling Vitiligo and ARDS - BriefGlance
Edesa Biotech 2Q Loss/Shr 49c >EDSA - Moomoo
Edesa Biotech Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Edesa Biotech, Inc. 2Q 2026: Revenue ($4.23M), Net income ($4.22M), EPS ($0.49) — 10-Q Summary - TradingView
Edesa Biotech (NASDAQ: EDSA) widens losses and warns of going concern risk - Stock Titan
Edesa Biotech reports Q2 FY2026 net loss $4.2M; cash $10.0M, working capital $8.2M - TradingView
Edesa Biotech Q2 net loss widens as R&D spending rises - TradingView
Edesa Biotech (NASDAQ: EDSA) ramps R&D as Q2 2026 loss reaches $4.2M - Stock Titan
Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results - GlobeNewswire
Drug data show ARDS treatment benefits as vitiligo trial nears - Stock Titan
What you need to know before buying Edesa (EDSA) (Underperforming) 2026-05-11Virgin POC - Newser
Number of shareholders of Edesa Biotech, Inc. – NASDAQ:EDSA - TradingView
Edesa Biotech Company Profile & Introduction - Moomoo
Edesa Biotech's Market Cap Up US$44m Following Year Of Insider Stock Buying - simplywall.st
Edesa Biotech (EDSA) CEO awarded 1,159 RSUs and reports updated share holdings - Stock Titan
Edesa Biotech, Inc. Common Shares (EDSA) Stock Price Today & Analysis - Gotrade
EDSA (Edesa) posts 39 percent positive EPS surprise for Q1 2026, shares jump 11.5 percent today.Quick Ratio - newser.com
Short Interest in Edesa Biotech, Inc. (NASDAQ:EDSA) Decreases By 32.5% - MarketBeat
EDSA - Finviz
Edesa Biotech reports FQ1 net loss of $2.2 million - MSN
EDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-Cap Biotech? - Stocktwits
Edesa Biotech Stock Soars 54%: What’s Driving the ARDS Drug Rally Now - TechStock²
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Edesa (EDSA) Stock: Should You Take Exposure (Investors Pile In) 2026-04-27Community Pattern Alerts - Newser
Edesa Biotech Reaches US$68m Market Cap Benefiting Insider Stock Buying - Yahoo Finance
EDSA Edesa Biotech Inc. Common Shares posts narrower Q1 2026 loss than consensus forecasts, shares gain on upbeat investor sentiment.Cost Structure - Cổng thông tin điện tử tỉnh Tây Ninh
Edesa Biotech Schedules Phase 2 Vitiligo Study for Mid-2026 - HarianBasis.co
Edesa (EDSA) Stock Insider Buying (Breakout Watch) 2026-04-20Most Discussed Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Edesa Biotech (EDSA) Reaffirms 2026 Clinical Study Timeline for Vitiligo Treatment - Yahoo Finance
Is Edesa (EDSA) Stock a Growth Stock? (Recovers) 2026-04-16MA Crossover - Cổng thông tin điện tử tỉnh Lào Cai
Edesa Biotech Inc Stock (EDSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Edesa Biotech Inc Stock (EDSA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nijhawan Pardeep | Chief Executive Officer |
Mar 10 '26 |
Buy |
6.60 |
1,000 |
6,599 |
628,813 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 05 '26 |
Buy |
3.90 |
10,000 |
39,000 |
402,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 04 '26 |
Buy |
4.26 |
10,000 |
42,560 |
392,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 03 '26 |
Buy |
3.63 |
10,000 |
36,300 |
382,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 02 '26 |
Buy |
2.00 |
2,000 |
4,000 |
627,813 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 02 '26 |
Buy |
2.28 |
1,000 |
2,280 |
372,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Feb 27 '26 |
Buy |
2.22 |
30,000 |
66,696 |
371,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Feb 26 '26 |
Buy |
1.58 |
20,571 |
32,480 |
615,797 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):